EXTON, PA — Melior Discovery recently announced it has been selected by SFA Therapeutics as a partner on SFA’s recently awarded “Save Our Start-ups” (SOS) grant. The award was issued by Ben Franklin Technology Partners of Southeastern Pennsylvania and the State of Pennsylvania.
In this important effort to counter the effects of the COVID-19 virus, SFA005 is expected to address the cytokine storm linked to Acute Respiratory Distress Syndrome (ARDS) experienced by patients infected with COVID-19.
It is being evaluated both as a preventative and a treatment in a validated liposaccharide challenge (LPS) animal model of ARDS. Success in this animal study would be an important precursor to human testing.
Dr. Ira Spector, CEO of SFA Therapeutics stated that, “The quest to overcome the effects of the COVID-19 virus is an effort vital to humanity. SFA welcomes the partnership of Melior Discovery and we are delighted that continued support from Ben Franklin Technology Partners and the State of Pennsylvania will enable us to draw upon our unique technology in that effort.”
“We are honored to be selected as a partner by Dr. Spector and his team for this important study,” said Andrew Reaume, CEO of Melior Discovery, Inc.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.